Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
59.90
-0.59 (-0.98%)
At close: Oct 30, 2026, 4:00 PM EDT
59.75
-0.15 (-0.25%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, Arrowhead Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $107.71. The average 1-year stock price forecast is 79.82% higher than the current stock price, while the lowest is $74 (+23.54%) and the highest is $126 (+110.35%).
Price Target: $107.71 (+79.82%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 9 | 10 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 2 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 12 | 12 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst UBS No rating | UBS | Buy Initiates $109 | Buy | Initiates | $109 | +81.97% | Oct 21, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 15, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $126 | Buy | Reiterates | $126 | +110.35% | Oct 15, 2026 |
| Citi | Citi | Buy Maintains $108 | Buy | Maintains | $108 | +80.30% | Oct 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $120 | Buy | Reiterates | $120 | +100.33% | Oct 14, 2026 |
Financial Forecast
Revenue This Year
464.14M
from 829.45M
Decreased by -44.04%
Revenue Next Year
328.22M
from 464.14M
Decreased by -29.28%
EPS This Year
-3.51
from -0.01
EPS Next Year
-4.98
from -3.51
EPS and Forward PE are based on non-GAAP adjusted numbers.